Cáncer de pulmón microcítico: revisión
Twenty percent of all lung cancers are of small cells (CPCP). More than half occur to people aged 60 and more. Due to its fast dissemination, most of them show symptoms when diagnosed (90%). These symptoms can be derived from its locoregional extension, metastases or can have a paraneoplastical orig...
Main Authors: | Carmen Guillén, María José Molina |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Universidad Complutense de Madrid
2006-01-01
|
Series: | Psicooncologia |
Subjects: | |
Online Access: | http://revistas.ucm.es/index.php/PSIC/article/view/16666 |
Similar Items
-
Cáncer de pulmón
by: Carlos Manzano, et al.
Published: (2023-07-01) -
Supervivencia extendida con pembrolizumab en un paciente con cáncer de pulmón no microcítico estadio IV
by: Isabel Santana Gómez, et al.
Published: (2023-12-01) -
Resultados en salud de PEMBROLIZUMAB como tratamiento de primera línea en cáncer de pulmón no microcítico
by: Paula Del Río Ortega
Published: (2022-03-01) -
Resultados en salud de PEMBROLIZUMAB como tratamiento de primera línea en cáncer de pulmón no microcítico
by: Paula Del Río Ortega
Published: (2022-03-01) -
Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
by: Dou Zhang, et al.
Published: (2024-01-01)